Benserazide-d3 (hydrochloride)

Benserazide-d3 (hydrochloride) is the deuterium labeled Benserazide hydrochloride (HY-B0404A) . Benserazide hydrochloride (Serazide) is an aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase inhibitor. Benserazide hydrochloride is also a PKM2 inhibitor. Benserazide hydrochloride directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up-regulation of OXPHOS. Benserazide hydrochloride can be used for the study of Parkinson's disease and melanoma[1][2][3].

Product Specifications

Product Name Alternative

Ro 4-4602-d3 (hydrochloride)

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Pyruvate Kinase

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Field of Research

Cancer; Neurological Disease

Solubility

10 mM in DMSO

Smiles

O=C(C(C([2H])([2H])O)([2H])N)NNCC1=CC=C(C(O)=C1O)O.Cl

Molecular Formula

C10H13D3ClN3O5

Molecular Weight

296.72

References & Citations

[1]Shen H, et al. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J Exp Med. 2003 Mar;199 (3) :149-59.|[2]Chandel TI, et al. A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin. Biochim Biophys Acta Proteins Proteom. 2019 Mar;1867 (3) :275-285.|[3]Zhou Y, et al. Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment. Int J Cancer. 2020 Jul 1;147 (1) :139-151.